Shoulder Osteoarthritis Clinical Trial
Official title:
Comparison of the Analgesic Efficacy of a Single Shot Interscalene Block With Liposomal Bupivacaine to Bupivacaine With Dexamethasone as an adjuvant-a Randomized Controlled Trial
NCT number | NCT03969875 |
Other study ID # | GCO 18-1264 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | August 18, 2018 |
Est. completion date | April 5, 2022 |
Verified date | April 2024 |
Source | Icahn School of Medicine at Mount Sinai |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Pain management after shoulder surgeries poses a unique challenge to the surgeon as well as the anesthesiologist. Regional anesthesia in the form of interscalene approach to the brachial plexus as an adjunct to general anesthesia or as a sole primary technique comes to one's rescue. Interscalene block either as single shot or as a catheter is an established modality for effective analgesia which facilitates early mobilization helping in physical therapy and early discharge. With the help of local anesthetic injected as a single shot, analgesia usually lasts less than 24 hours. Recent research in regional anesthesia is advancing towards adjuvants which will prolong the duration of local anesthesia. This has introduced the concept of "multimodal perineural analgesia (MMPNA)" whereby multiple agents with differing mechanisms of action are used with the goal of providing perineural analgesia while avoiding exposure to high and potentially toxic levels of individual agents. Some of the commonly used adjuvants in clinical studies are fentanyl, buprenorphine, morphine, tramadol, magnesium, epinephrine, ketamine, non-steroidal anti-inflammatory drug (NSAID), midazolam, parecoxib, ketorolac, clonidine, dexmedetomidine, dexamethasone, neostigmine and potassium. They find a distinct place in wide spread clinical practice as an off-label use. Steroids have a long history of safe use in epidural space for treatment of radicular pain due to nerve irritation. Dexamethasone is used routinely as a part of anti- emetic prophylaxis and anti-inflammatory effect. Methyl prednisone was the first steroid to be used as an adjuvant. Dexamethasone was first used as an adjuvant in 2003. It has been hypothesized that steroids induce a degree of vasoconstriction, thereby reducing local anesthetic absorption, tend to have an opioid sparing effect. Another theory suggests that it increases the activity of inhibitory potassium channels on nociceptive C-fibers (via glucocorticoid receptors), thus decreasing their activity. Several studies have demonstrated promising results with the use of 8mg of perineural dexamethasone. No neuronal injury has been reported in in vivo studies. Though there are several studies which report usage of dexamethasone in varying doses of 2mg to 8mg, the optimal effective dose of dexamethasone as an adjuvant for nerve block remains unknown. Some studies have suggested perineural is more effective than IV as an adjuvant . Liposomal bupivacaine, a formulation where bupivacaine is encapsulated into multivesicular liposomes, making it a slow and controlled release from the liposomes, was originally indicated for wound infiltration at the surgical site to provide post-surgical analgesia. Studies have demonstrated efficacy up to 24 hours in femoral nerve block in total knee arthroplasty. Recent approval of liposomal bupivacaine in interscalene block for shoulder surgeries by FDA opens an arena unexplored in the world of regional anesthesia. Current opioid epidemic, a crisis in health care forces healthcare providers to consider alternate analgesic modalities without compromising patient comfort. Regional anesthesia has revolutionized peri-operative pain management by avoiding opioids and their side effects. Use of adjuvants to the current regional techniques holds promise in postsurgical analgesia. The researchers propose to compare the analgesic efficacy of liposomal bupivacaine to bupivacaine with dexamethasone as an adjuvant in interscalene block with catheters for shoulder surgeries. Till date, there is not a single study comparing the three in current literature.
Status | Completed |
Enrollment | 90 |
Est. completion date | April 5, 2022 |
Est. primary completion date | April 5, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - All patients between age 18-80 years undergoing elective primary total shoulder arthroplasty procedure. - All patients who speak read and understand English will be included for follow up purposes. Exclusion Criteria: - Patient refusal - ASA 5 - presence of coagulopathy - severe lung disease - contralateral diaphragmatic palsy - insulin-dependent diabetes - hepatic disease/failure - kidney disease/failure - pregnancy - chronic opioid use (defined as opioid use for >3 months), or allergy to any of the study medications. |
Country | Name | City | State |
---|---|---|---|
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai |
United States,
Abdallah FW, Brull R. Facilitatory effects of perineural dexmedetomidine on neuraxial and peripheral nerve block: a systematic review and meta-analysis. Br J Anaesth. 2013 Jun;110(6):915-25. doi: 10.1093/bja/aet066. Epub 2013 Apr 15. — View Citation
Bishop JY, Sprague M, Gelber J, Krol M, Rosenblatt MA, Gladstone J, Flatow EL. Interscalene regional anesthesia for shoulder surgery. J Bone Joint Surg Am. 2005 May;87(5):974-9. doi: 10.2106/JBJS.D.02003. — View Citation
Vandepitte C, Kuroda M, Witvrouw R, Anne L, Bellemans J, Corten K, Vanelderen P, Mesotten D, Leunen I, Heylen M, Van Boxstael S, Golebiewski M, Van de Velde M, Knezevic NN, Hadzic A. Addition of Liposome Bupivacaine to Bupivacaine HCl Versus Bupivacaine HCl Alone for Interscalene Brachial Plexus Block in Patients Having Major Shoulder Surgery. Reg Anesth Pain Med. 2017 May/Jun;42(3):334-341. doi: 10.1097/AAP.0000000000000560. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Numerical Rating Score for Pain | Numerical rating score for pain is assessed from 0 to 10, with 0 being no pain and 10 being worst pain. | at 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, 48 hours | |
Secondary | Time to First Analgesic Request | Time to first analgesic request on Day 1 | Day 1 | |
Secondary | Total Narcotic Consumption | Total narcotic consumption in mg morphine equivalents (MME) during hospital stay | hospital stay, up to 48 hours | |
Secondary | Arm Weakness | Arm weakness as assessed by flexion and extension at wrist -- total scale from 1 to 10, with 10 being most weakness | at 6 hours, 12 hours, 18 hours, 24 hours, 36 hours | |
Secondary | Arm Numbness | Arm numbness assessed by the sensation at deltoid area. Sensation total scale from 1 to 10, with higher number indicating most sensation. | at 6 hours, 12 hours, 18 hours, 24 hours, 36 hours | |
Secondary | Time of Analgesia Duration | The duration for which the patient has no pain on Day 1 | Day 1 | |
Secondary | Time of Motor Recovery | Time of motor recovery on Day 1 | Day 1 | |
Secondary | Sensory Intact | Sensory testing by using pinprick in the region of C5 dermatome. Scale from 1 to 10, with higher score indicating more sensation. | at 6 hours, 12 hours, 18 hours, 24 hours, 36 hours | |
Secondary | Hand Strength | Hand strength assessed by using dynamometer, a device for measuring the amount of static force that can squeeze around a dynamometer, in kilograms. | at 6 hours, 12 hours, 18 hours, 24 hours, 36 hours | |
Secondary | PACU Length of Stay | Post-anesthesia Care Unit length of stay in hours on Day 1 | Day 1 | |
Secondary | Hospital Length of Stay | Length of stay for duration of hospital admission | up to 3 days | |
Secondary | Number of Complication Events | Number of complications - any associated complications like nausea, vomiting, dizziness, horner's syndrome, hoarseness and dyspnea | up to 3 days | |
Secondary | Number of Participants With Quality of Sleep Rating | Patient to rate their quality of sleep as good, average, or bad | average of 3 days | |
Secondary | Number of Participants With Patient's Satisfaction | Number of Participants with Patient satisfaction. Patients were asked if they were satisfied. | during the hospital stay, up to 3 days | |
Secondary | Change in Patient Reported Outcomes Measurement Information System (PROMIS) | PROMIS global assessment assesses physical and mental activities of daily living scored from 0 (poor) to 5 (excellent) at first post-operative visit as compared to baseline. Each scale from 0-100, higher score indicates better health outcomes. | baseline and one week post-op |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03540030 -
Opioid-Free Shoulder Arthroplasty
|
Phase 4 | |
Recruiting |
NCT06025331 -
Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA?
|
N/A | |
Recruiting |
NCT06153381 -
Virtual Rehabilitation Assistant Via Instant Messaging Communication to Promote Adherence to Rehabilitation After Reverse Shoulder Replacement
|
N/A | |
Recruiting |
NCT04762667 -
Individual Preoperative Planning for RSA
|
N/A | |
Recruiting |
NCT06025448 -
Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability?
|
N/A | |
Completed |
NCT03854357 -
Subscapularis Strength After Total Shoulder Arthroplasty
|
N/A | |
Recruiting |
NCT05408065 -
Comparison of the Analgesic Effect of 2 Shoulder Infiltrations
|
N/A | |
Recruiting |
NCT05048264 -
Effect of Corticosteroid Injections on Blood Glucose
|
||
Recruiting |
NCT05395819 -
Clinical Evaluation of Reverse Versus Anatomic Shoulder Arthroplasty Techniques in the Treatment of Osteoarthritis
|
N/A | |
Recruiting |
NCT06381791 -
CBD for Pain Following Orthopedic Shoulder Surgery
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04405297 -
A Disease-based Treatment Study for Diagnosed Osteoarthritis Utilizing Adipose-derived Regenerative Cells
|
||
Not yet recruiting |
NCT05868330 -
Comparison of Interscalene Catheter to Single Injection Interscalene Blocks for Total Shoulder Arthroplasties
|
N/A | |
Recruiting |
NCT05675527 -
PRP for Glenohumeral Osteoarthritis
|
Phase 4 | |
Recruiting |
NCT06319911 -
AETOS Shoulder System
|
||
Withdrawn |
NCT03474510 -
Effective Pain Management During Shoulder Replacement Surgery With EXPAREL
|
Phase 4 | |
Completed |
NCT05043493 -
Effect of PRP as Therapy for Shoulder Osteoarthritis
|
N/A | |
Recruiting |
NCT05788614 -
Retroversion in Reverse Shoulder Arthroplasty
|
N/A | |
Not yet recruiting |
NCT06435494 -
Cross-sectorial Use of Patient-Reported Outcomes in Chronic Degenerative Shoulder Conditions
|
N/A | |
Withdrawn |
NCT04285606 -
Effect of Postop Rehab Methods on Outcomes Following Reverse Shoulder Arthroplasty
|
N/A | |
Recruiting |
NCT04984291 -
Zimmer Biomet Shoulder Arthroplasty PMCF
|
N/A |